reports
SQI Diagnostics Expanding Business into Rapid Diagnostic Testing Marke...
SQI Diagnostics Expanding Business into Rapid Diagnostic Testing Market Novel Diagnostics Target Organ Transplant, Autoimmune Disease and Serological Testing, Including Two Rapid Tests for COVID-19 TORONTO, Sept. 09, 2020 (GLOBE NEWSWIRE) -- SQI Diagnostics, Inc. (TSX-V: SQD; OTCQX-US: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced it is expanding its proprietary rapid diagnostic testing portfolio targeting organ transplant, ...
SQI Diagnostics Appoints Rob Chioini as Chief Executive Officer, Grant...
SQI Diagnostics Appoints Rob Chioini as Chief Executive Officer, Grants Options and Amends Stock Option Plan Accomplished Medical Device and Pharma Executive Brings Proven Record of Building Value in Life Science Companies TORONTO, Aug. 18, 2020 (GLOBE NEWSWIRE) -- SQI Diagnostics, Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that the Company’s board of directors has appointed Robert L. Chioini as Chief Executive...
Ford Equity International Rating and Forecast Report
Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind...
Update: Tapping into considerable market opportunities
SQI has made steady progress over recent months in signing new agreements with drug development companies in its high-volume assay business. Encouragingly, service revenues are now booked for custom-made tests early on in development, albeit at modest levels. While the conversion of customers from early contract work/validation to meaningful revenue-generating accounts is slower than expected, industry interest continues to grow steadily for SQI’s multiplexing technology capabilities, as does ...
Outlook: Gaining momentum
SQI has continued its positive momentum over the last year, signing five service agreements with drug development companies. The company also broadened its commercial focus in 2014 with a deal to automate DNA-based pathogen detection assays, a new application for its technology. We now look towards the conversion of customers from early contract work/validation to full commercialisation. Despite the encouraging deal progress, we reduce our valuation to C$55m vs C$60m previously (C$0.98 per share...
Update: Encouraging new deal flow
SQI has had positive traction in recent months with the signing of two new customers, a top 10 global pharma company and a UK-based DNA specialist. The latter will use SQI’s systems for pathogen detection, potentially opening the door to a new application for SQI’s technology. These deals counteract what has proven to be a more protracted timeframe than anticipated for the full commercialisation of SQI’s diagnostics platform. After pushing back the phasing of contracts converting to full c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.